Microfluidic platforms in diagnostic of ovarian cancer

Environ Res. 2023 Nov 15;237(Pt 2):117084. doi: 10.1016/j.envres.2023.117084. Epub 2023 Sep 6.

Abstract

The most important reason for death from ovarian cancer is the late diagnosis of this disease. The standard treatment of ovarian cancer includes surgery and chemotherapy based on platinum, which is associated with side effects for the body. Due to the nonspecific nature of clinical symptoms, developing a platform for early detection of this disease is needed. In recent decades, the advancements of microfluidic devices and systems have provided several advantages for diagnosing ovarian cancer. Designing and manufacturing new platforms using specialized technologies can be a big step toward improving the prevention, diagnosis, and treatment of this group of diseases. Organ-on-a-chip microfluidic devices are increasingly used as a promising platform in cancer research, with a focus on specific biological aspects of the disease. This review focusing on ovarian cancer and microfluidic application technologies in its diagnosis. Additionally, it discusses microfluidic platforms and their potential future perspectives in advancing ovarian cancer diagnosis.

Keywords: Cell-on-chip; Diagnosis; Microfluidic system; Organs-on-chip; Ovarian cancer.

Publication types

  • Review